Expression and purification of a recombinant ELRL-MAP30 with dual-targeting anti-tumor bioactivity

Chen, Weiwei; Zhang, Hongrui; Huang, Zhi‐Guang; Zhou, Zhe-yue; Lou, Qiuwen; Jiang, Xinyi; Zhu, Ziling

doi:10.1016/j.pep.2021.105893

Cited by 5 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MAP30 is a ribosome-inactivating protein (RIP) isolated from bitter gourd that has good antitumor activity [24]. However, due to its lack of tumor targeting, it has significant toxic side effects and limited clinical applications.…”

Section: Introductionmentioning

confidence: 99%

Fusion of dual-targeting peptides with MAP30 promotes the apoptosis of MDA-MB-231 breast cancer cells

Wang,

Yang,

Chen

et al. 2024

Preprint

View full text Add to dashboard Cite

Momordica antiviral protein 30 kDa (MAP30) is a type I ribosome-inactivating protein (RIP) with antibacterial, anti-HIV and antitumor activities but lacks the ability to target tumor cells. To increase its tumor-targeting ability, the arginine-glycine-aspartic (RGD) peptide and the epidermal growth factor receptor interference (EGFRi) peptide were fused with MAP30, which was named ELRL-MAP30. The use of targeted therapy for triple-negative breast cancer (TNBC) MDA-MB-231 cells, which lack the expression of estrogen receptor (ER), Progesterone receptor (PgR) and human epidermal growth factor receptor-2 (HER2), is limited. In this study, we focused on exploring the effect and mechanism of ELRL-MAP30 on TNBC MDA-MB-231 cells. First, we discovered that ELRL-MAP30 significantly inhibited the migration and invasion of MDA-MB-231 cells and induced MDA-MB-231 cell apoptosis. Moreover, ELRL-MAP30 treatment significantly reduced Bcl-2 protein expression and increased BAX protein expression. Furthermore, ELRL-MAP30 triggered apoptosis via the Fak/EGFR/Erk and Ilk/Akt signaling pathways. In addition, recombinant ELRL-MAP30 can also inhibit chicken embryonic angiogenesis, indicating its potential therapeutic effects on tumor angiogenesis. Collectively, these results indicate that ELRL-MAP30 has significant tumor-targeting properties in MDA-MB-231 cancer cells and reveals potential therapeutic effects on angiogenesis. These findings indicate the potential role of ELRL-MAP30 in the targeted treatment of the TNBC cell line MDA-MB-231.

show abstract

Section: Introductionmentioning

confidence: 99%

Fusion of dual-targeting peptides with MAP30 promotes the apoptosis of MDA-MB-231 breast cancer cells

Wang,

Yang,

Chen

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Innovative Diagnostic Peptide‐Based Technologies for Cancer Diagnosis: Focus on EGFR‐Targeting Peptides

et al. 2022

View full text Add to dashboard Cite

Active targeting using biological ligands has emerged as a novel strategy for the targeted delivery of diagnostic agents to tumor cells. Conjugating functional targeting moieties with diagnostic probes can increase their accumulation in tumor cells and tissues, enhancing signal detection and, thus, the sensitivity of diagnosis. Due to their small size, ease of chemical synthesis and site‐specific modification, high tissue penetration, low immunogenicity, rapid blood clearance, low cost, and biosafety, peptides offer several advantages over antibodies and proteins in diagnostic applications. Epidermal growth factor receptor (EGFR) is one of the most promising cancer biomarkers for actively targeting diagnostic and therapeutic agents to tumor cells due to its active involvement and overexpression in various cancers. Several peptides for EGFR‐targeting have been identified in the last decades, which have been obtained by multiple means including derivation from natural proteins, phage display screening, positional scanning synthetic combinatorial library, and in silico screening. Many studies have used these peptides as a targeting moiety for diagnosing different cancers in vitro, in vivo, and in clinical trials. This review summarizes the progress of EGFR‐targeting peptide‐based assays in the molecular diagnosis of cancer.

show abstract

Production and Evaluation of In-vitro and In-vivo Effects of P28-IL24, a Promising Anti-breast Cancer Fusion Protein

Ghavimi

Akbari

Jahanian-Najafabadi

2021

Int J Pept Res Ther

View full text Add to dashboard Cite

Expression and purification of a recombinant ELRL-MAP30 with dual-targeting anti-tumor bioactivity

Cited by 5 publications

References 35 publications

Fusion of dual-targeting peptides with MAP30 promotes the apoptosis of MDA-MB-231 breast cancer cells

Fusion of dual-targeting peptides with MAP30 promotes the apoptosis of MDA-MB-231 breast cancer cells

Innovative Diagnostic Peptide‐Based Technologies for Cancer Diagnosis: Focus on EGFR‐Targeting Peptides

Production and Evaluation of In-vitro and In-vivo Effects of P28-IL24, a Promising Anti-breast Cancer Fusion Protein

Contact Info

Product

Resources

About